Company / Current Assets
Foghorn Therapeutics Inc. Current Assets History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$163.2M
FY2025
5-year range
$163.2M / $351.4M
FY2021-FY2025
Trend
-34.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has fluctuated over the past 6 years, ranging from $163M in FY2025 to $351M in FY2022.
Based on SEC 10-K filings.
$163M in FY2025 with a 5-year CAGR of -3.1%.
Declined from $240M to $163M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -22.6%
- 5-Year CAGR
- -3.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.1%, indicating a declining trend.
- In FY2025, current assets decreased 34.6% year-over-year.
- Peak current assets was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $163.2M | -34.6% |
| FY2024 | $249.6M | +3.9% |
| FY2023 | $240.2M | -31.7% |
| FY2022 | $351.4M | +84.3% |
| FY2021 | $190.7M | +0.0% |
| FY2020 | $190.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026